Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

167
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
167
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

323
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
323
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Air-permeable hydrogels through viscoelastic phase separation of aerogels.

Nature·2026
Same author

Antibiotics stimulate protein transfer to persister cells.

Science (New York, N.Y.)·2026
Same author

Ion-triggered reconfigurable hydrogels with salt-enhanced mechanical and swelling properties via network topological adaptation.

Nature communications·2026
Same author

Implantable living materials autonomously deliver therapeutics using contained engineered bacteria.

Science (New York, N.Y.)·2026
Same author

Rapid fabrication of solvent-compatible NOA 81 microfluidic devices for double-emulsion microfluidics.

Lab on a chip·2026
Same author

Green Oil-in-Water Nanoemulsions for Delivery of Phytochemicals With Pesticidal Activity for Sustainable Food Production and Safety.

Comprehensive reviews in food science and food safety·2026

Related Experiment Video

Updated: May 6, 2026

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes
09:51

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes

Published on: March 3, 2020

8.9K

Microfluidic templated mesoporous silicon-solid lipid microcomposites for sustained drug delivery.

Dongfei Liu1, Bárbara Herranz-Blanco, Ermei Mäkilä

  • 1Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki , FI-00014 Helsinki, Finland.

ACS Applied Materials & Interfaces
|November 2, 2013
PubMed
Summary

This study developed novel microcomposite drug carriers by encapsulating porous silicon microparticles within solid lipid microparticles. These enhanced carriers improve drug delivery by offering better biocompatibility and controlled release of various therapeutics.

More Related Videos

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

10.7K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.4K

Related Experiment Videos

Last Updated: May 6, 2026

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes
09:51

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes

Published on: March 3, 2020

8.9K
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

10.7K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.4K

Area of Science:

  • Biomaterials Science
  • Drug Delivery Systems
  • Nanotechnology

Background:

  • Developing stable, biocompatible drug carriers with controlled release is a significant challenge.
  • Thermally hydrocarbonized porous silicon (THCPSi) microparticles have limitations for drug delivery.
  • Solid lipid microparticles (SLMs) offer potential for improved drug carrier formulations.

Purpose of the Study:

  • To engineer stable drug carriers by encapsulating THCPSi microparticles within SLMs.
  • To optimize formulation and process factors for creating monodisperse, stable SLMs.
  • To evaluate the drug release profiles, cytocompatibility, and morphology of the novel microcomposites.

Main Methods:

  • Utilized microfluidic techniques for encapsulating THCPSi microparticles into SLMs.
  • Optimized lipid matrixes, organic solvents, emulsifiers, and solvent evaporation methods.
  • Characterized the microcomposites using FTIR and confocal microscopy.
  • Assessed drug release kinetics for both water-soluble and water-insoluble drugs at various pH levels.
  • Evaluated cytocompatibility with Caco-2 and HT-29 intestinal cancer cells.

Main Results:

  • Successfully fabricated monodisperse THCPSi-solid lipid microcomposites (THCPSi-SLMCs) with spherical morphology.
  • Confirmed the deposition of THCPSi microparticles within the SLM matrix via FTIR and confocal imaging.
  • Demonstrated enhanced cytocompatibility of THCPSi-SLMCs with intestinal cancer cells.
  • Achieved prolonged drug release, with 50% payload release at least 1.3 times longer than from THCPSi microparticles alone.
  • Showcased sustained release of both water-soluble and water-insoluble drugs, with a reduced burst-release effect.

Conclusions:

  • THCPSI-SLMCs represent an advanced drug delivery platform overcoming limitations of bare THCPSi microparticles.
  • The fabricated microcomposites exhibit enhanced biocompatibility and controlled release capabilities.
  • This technology holds promise for developing effective and tunable drug delivery systems for various therapeutics.